Does the combination of hydroxychloroquine (Plaquenil) and nitrofurantoin (Macrobid) increase the risk of peripheral neuropathy?

Does the Combination of Hydroxychloroquine and Nitrofurantoin Increase Peripheral Neuropathy Risk?

Yes, combining hydroxychloroquine (Plaquenil) and nitrofurantoin (Macrobid) does increase the risk of peripheral neuropathy because both drugs independently cause this adverse effect, creating an additive risk when used together.

Individual Drug Neuropathy Risks

Nitrofurantoin (Macrobid)

The FDA drug label explicitly warns that peripheral neuropathy may become severe or irreversible with nitrofurantoin use 1. This risk is heightened in patients with:

• Renal impairment (creatinine clearance <60 mL/min)
• Anemia
• Diabetes mellitus
• Electrolyte imbalance
• Vitamin B deficiency
• Debilitating disease

Clinical case reports confirm nitrofurantoin can cause distinctive non-length-dependent small-fiber neuropathy with clustered terminal nerve swellings 2. Recovery is often slow or incomplete, and the neuropathy may be irreversible even after drug discontinuation 3. Importantly, this toxicity is not consistently dose-dependent and can occur even without renal dysfunction 2.

Hydroxychloroquine (Plaquenil)

Hydroxychloroquine carries a documented risk of peripheral neuropathy, though less commonly emphasized than its retinal toxicity. The FDA label for Plaquenil does not prominently feature peripheral neuropathy warnings 4, but multiple guidelines confirm this risk:

• Prolonged therapy can cause toxic myopathy, cardiomyopathy, and peripheral neuropathy that improve if the drug is promptly withdrawn 5
• A 2020 oncology guideline specifically warns that hydroxychloroquine incurs a risk of peripheral neuropathy, requiring vigilance particularly in patients receiving platinum salts, anthracyclines, taxanes, or immunomodulators, and especially with comorbidities like diabetes or chronic alcohol abuse 6
• Clinical case series document hydroxychloroquine-induced neuromyotoxicity with slow and potentially incomplete resolution after discontinuation 7, 8

Additive Risk with Combination Therapy

When both drugs are prescribed together, the neuropathy risk becomes additive rather than synergistic. Each drug independently damages peripheral nerves through distinct mechanisms:

• Nitrofurantoin causes axonal degeneration affecting dorsal root ganglia
• Hydroxychloroquine causes toxic effects on Schwann cells and myelin

The 2020 COVID-19 oncology guideline explicitly states that hydroxychloroquine's peripheral neuropathy risk requires heightened vigilance when combined with other neurotoxic agents 6. While this guideline addresses chemotherapy combinations, the principle directly applies to nitrofurantoin given its established neurotoxicity.

Clinical Management Algorithm

Before Prescribing This Combination:

1. Assess baseline neuropathy risk factors:

   • Check renal function (creatinine clearance)
   • Screen for diabetes, vitamin B12 deficiency, alcohol abuse
   • Document any pre-existing neuropathy symptoms
   • Review all concurrent medications for neurotoxic potential

2. Consider alternatives if ANY high-risk factors present:

   • For UTI: Use alternative antibiotics (trimethoprim-sulfamethoxazole, fosfomycin, cephalosporins)
   • For autoimmune conditions: Discuss risk-benefit with rheumatology

3. If combination is unavoidable:

   • Use the shortest possible duration of nitrofurantoin (3-7 days for acute UTI, avoid chronic suppression)
   • Ensure hydroxychloroquine dose ≤5.0 mg/kg actual body weight 9
   • Obtain baseline neurological examination documenting sensation, reflexes, and strength

During Treatment Monitoring:

• Question patient at each visit about new numbness, tingling, burning pain, or weakness in hands/feet
• If any neuropathic symptoms develop: immediately discontinue nitrofurantoin (the more acutely neurotoxic agent)
• Consider discontinuing hydroxychloroquine if symptoms are severe or progressive
• Do not wait for electrophysiological confirmation—clinical diagnosis is sufficient 10, 11

Common Pitfalls to Avoid:

1. Do not use nitrofurantoin for chronic UTI suppression in patients on hydroxychloroquine—the prolonged exposure dramatically increases neuropathy risk
2. Do not assume normal renal function excludes risk—nitrofurantoin neuropathy occurs even with normal kidney function 2
3. Do not dismiss early sensory symptoms as benign—peripheral neuropathy from these drugs can become irreversible 1, 3
4. Do not rechallenge with nitrofurantoin if neuropathy develops—case reports show symptom recurrence with re-exposure 12

Evidence Quality Considerations

The evidence linking both drugs to peripheral neuropathy is strong, derived from FDA drug labels 1, 4, multiple clinical practice guidelines 6, 5, and consistent case reports [2-8]. While no studies specifically examine the combination of hydroxychloroquine plus nitrofurantoin, the principle of additive neurotoxicity with multiple neurotoxic agents is well-established in oncology guidelines addressing chemotherapy-induced peripheral neuropathy 6, 10, 11.

The absence of specific combination studies should not provide false reassurance—both drugs independently cause peripheral neuropathy through different mechanisms, making additive toxicity biologically plausible and clinically concerning.